Skip to content

Latest expert network news

Stay up to date with the latest news from Techspert, and read updates and insights from the many industries we work in

Featured

Techspert's Milestone Achievement in the Financial Times 1000 List

Techspert's recognition as the 539th placement in the Financial Times 1000: Europe’s Fastest Growing Companies underscores our commitment to revolutionizing how expert insights are accessed and applied in the healthcare and life sciences sectors....

Read more

Latest Posts

Featured
,
Market Trends, Access & Sizing

October 2025 AI in Healthcare & Life Sciences: Strategy, Access & GTM Roundup

This month, we spotlight how AI adoption in healthcare and life sciences is beginning to show tangible outcomes that matter for decision‑makers. Each development reveals where real progress is taking hold, and where informed action can start today. And they all share a clear thread; AI has moved past proof‑of‑concept and is increasingly embedded in the systems that connect discovery, diagnostics, and delivery. Across therapeutic areas, AI systems are now validated by regulators, embedded in enterprise infrastructure, and woven into compliance workflows. For commercial and strategy teams, this creates a new dynamic, not just faster discovery, but shifting economics in how therapies are positioned, priced, and accessed. This roundup filters the noise to focus on the verified developments with the greatest implications for timing, differentiation, and market behavior.

Read more
Featured
,
Market Trends, Access & Sizing

Why Addiction Demands a Place in Your Primary Research Agenda

Addiction and Alcohol Use Disorder (AUD) are among the most persistent public health challenges worldwide. What was once a blind spot is now quickly moving into focus across Primary Market Research. Over the past 9 months, Techspert has seen a 43% rise in requests for expertise focused on addiction, compared to the entire year of 2024. This topic now sits on real budgets and roadmaps. Policy reform, payer pilots, and new clinical evidence are all shaping coverage and investment decisions. The quality of your primary insight determines the outcome.

Read more
Featured
,
Market Trends, Access & Sizing

Why Big‑Pharma’s Direct‑to‑Consumer Pivot Belongs on Your 2026 Checklist

Drug makers such as Roche, Lilly, and Novo Nordisk are starting to sell medicines straight to U.S. patients. If pharmacy benefit managers (PBMs) lose their middle‑man role, every forecast that still assumes a big rebate line could be wrong overnight, and your 2026 strategy could already be outdated.

Read more

All articles

Finding new voices for your market research

Start my project 

Mask Group 8